EXELIXIS INC
For the period ended Dec 29, 2023. Filed Feb 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 6, 2024
EXEL$71.74+3.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except per share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $262,994 | $501,195 |
| Short-term investments | 732,308 | 807,273 |
| Trade receivables, net | 237,407 | 214,784 |
| Inventory | 17,323 | 33,299 |
| Prepaid expenses and other current assets | 67,926 | 62,211 |
| Total current assets | 1,317,958 | 1,618,762 |
| Long-term investments | 728,717 | 756,731 |
| Property and equipment, net | 128,731 | 110,624 |
| Deferred tax assets, net | 361,145 | 231,110 |
| Goodwill | 63,684 | 63,684 |
| Right-of-use assets and other | 342,122 | 290,578 |
| Total assets | $2,942,357 | $3,071,489 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $33,768 | $32,667 |
| Accrued compensation and benefits | 93,325 | 77,158 |
| Accrued clinical trial liabilities | 71,615 | 65,072 |
| Rebates and fees due to customers | 59,619 | 50,350 |
| Accrued collaboration liabilities | 27,533 | 20,188 |
| Other current liabilities | 108,417 | 78,924 |
| Total current liabilities | 394,277 | 324,359 |
| Long-term portion of operating lease liabilities | 189,944 | 190,170 |
| Other long-term liabilities | 94,224 | 68,533 |
| Total liabilities | 678,445 | 583,062 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued | — | — |
| Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 302,793 and 323,951 at December 31, 2023 and 2022, respectively | 303 | 324 |
| Additional paid-in capital | 2,440,710 | 2,536,849 |
| Accumulated other comprehensive loss | (3,750) | (14,521) |
| Accumulated deficit | (173,351) | (34,225) |
| Total stockholders’ equity | 2,263,912 | 2,488,427 |
| Total liabilities and stockholders’ equity | $2,942,357 | $3,071,489 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.